
NASDAQ · BTAI
BioXcel Therapeutics, Inc.
Healthcare · Biotechnology
$0.07
Up+$0.03 (+64.22%)
Updated Nov 17, 2026, 6:04 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 45.49M
- P/E ratio
- -0.32
- Dividend yield
- 0.00%
- 52-week range
- $0.07 – $4.29
- Volume
- 47.48M
- Avg. volume
- 961.53K
Price performance · BTAI
BTAI price history
1M range · 0 trading sessions · Daily adjusted prices
BTAI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest BTAI news
The latest Smart Investors Daily articles mentioning BTAI.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BTAI research
Overview
Company profile and research snapshot.
Company profile
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $12.00
- Implied upside
- —
- Analysts
- 11
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 2, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 17, 2026 | Rodman & Renshaw | Buy | — |
| Mar 5, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 15, 2025 | HC Wainwright & Co. | Buy | — |
| Sep 12, 2025 | Mizuho | Neutral | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.

